Articles

Efficacy of bortezomib, cyclophosphamide and dexamethasone in treatment-naïve patients with high-risk cardiac AL amyloidosis (Mayo Clinic stage III)

National Amyloidosis Center and Hematology Unit, CHU Limoges, France
Tufts Medical Center, Boston, MA, USA
Medical College of Wisconsin, Milwaukee, WI, USA
Centre for Amyloidosis and Acute Phase Proteins, University College London Medical School, UK
Hematology Unit, CHU Toulouse, France
Hematology Unit, CH Lens, France
Hematology Unit, CHU Caen, France
Internal Medicine Units, CHU Bordeaux, France
Internal Medicine Units, CHU Bordeaux, France
National Amyloidosis Center and Cardiology Unit, CHU Limoges, France
Internal Medicine Units, CHU Bordeaux, France
Internal Medicine Unit, CHU Rennes, France
Centre for Amyloidosis and Acute Phase Proteins, University College London Medical School, UK
National Amyloidosis Center and Hematology Unit, CHU Limoges, France
Nephrology Unit, CHU Poitiers, France
Centre for Amyloidosis and Acute Phase Proteins, University College London Medical School, UK
Centre for Amyloidosis and Acute Phase Proteins, University College London Medical School, UK;Cross Cancer Institute, University of Alberta, Edmonton, Canada
Vol. 99 No. 9 (2014): September, 2014 https://doi.org/10.3324/haematol.2014.104109